Aptahem Valuation

Is APTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of APTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate APTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate APTA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for APTA?

Key metric: As APTA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for APTA. This is calculated by dividing APTA's market cap by their current revenue.
What is APTA's PS Ratio?
PS Ratio	3x
Sales	SEK 2.65m
Market Cap	SEK 7.25m

APTA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	-0.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does APTA's PS Ratio compare to its peers?

The above table shows the PS ratio for APTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.1x
CYXO Cyxone	3.1x	n/a	SEK 15.8m
PROGEN Prostatype Genomics	1.9x	n/a	SEK 7.9m
LPGO Lipigon Pharmaceuticals	2.7x	114.4%	SEK 19.2m
EURI B European Institute of Science	4.6x	n/a	SEK 4.0m
APTA Aptahem	3x	n/a	SEK 7.8m

Price-To-Sales vs Peers: APTA is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does APTA's PS Ratio compare vs other companies in the SE Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
XBRANE Xbrane Biopharma	1.5x	61.1%	US$28.14m
SPRINT Sprint Bioscience	1.7x	27.6%	US$9.55m
PMDS PMD Device Solutions	0.8x	62.0%	US$3.29m
GEAN Genetic Analysis	1x	n/a	US$2.32m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: APTA is good value based on its Price-To-Sales Ratio (3x) compared to the Swedish Biotechs industry average (11.8x).

Price to Sales Ratio vs Fair Ratio

What is APTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate APTA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£154.5b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

-1.8%

4.5%

PMD Device Solutions

SEK 36.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

-14.7%

n/a

Swedish Orphan Biovitrum

SEK 99.5b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

-12.4%

15.7%